(Total Views: 924)
Posted On: 10/24/2024 11:14:19 PM
Post# of 154867
GSK owns 27% Samsung Bio.
https://www.fiercepharma.com/manufacturing/gs...l-one-296m
Look @ TaiMed.
Quest is doing a trial funded by TaiMed.
TaiMed is a Samsung partner.
GSK = Samsung Cytodyn re-structure = TaiMed future LL manufacturing?
https://www.taimedbiologics.com/article_d.php...mp;id=1790
___
& GSK does do DD & buy individual indications.
This sound like something Max is now possibly doing for GSK ?
"Initial phase to identify and accelerate promising scientific concepts for further research starting in respiratory and immunology"
" From these explorations, the collaboration aims to identify a portfolio of up to 10 novel medicines and vaccines which will each be subject to an exclusive option by GSK for further clinical development. Under the terms of the agreement, Flagship and its bioplatform companies will be eligible to receive up to $720 million in upfront, development and commercial milestones from GSK, as well as preclinical funding and tiered royalties, for each acquired programme."
https://www.gsk.com/en-gb/media/press-release...-vaccines/
https://www.fiercepharma.com/manufacturing/gs...l-one-296m
Look @ TaiMed.
Quest is doing a trial funded by TaiMed.
TaiMed is a Samsung partner.
GSK = Samsung Cytodyn re-structure = TaiMed future LL manufacturing?
https://www.taimedbiologics.com/article_d.php...mp;id=1790
___
& GSK does do DD & buy individual indications.
This sound like something Max is now possibly doing for GSK ?
"Initial phase to identify and accelerate promising scientific concepts for further research starting in respiratory and immunology"
" From these explorations, the collaboration aims to identify a portfolio of up to 10 novel medicines and vaccines which will each be subject to an exclusive option by GSK for further clinical development. Under the terms of the agreement, Flagship and its bioplatform companies will be eligible to receive up to $720 million in upfront, development and commercial milestones from GSK, as well as preclinical funding and tiered royalties, for each acquired programme."
https://www.gsk.com/en-gb/media/press-release...-vaccines/
(13)
(0)
